Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simbrinza vs its components in glaucoma and ocular hypertension
NCT01310777Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- May 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of brinzolamide and brimonidine in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Alcon Inc. Primary endpoint: Mean Diurnal Intraocular Pressure Change From Baseline at 3 months. Started May 2011; status: completed.
02
Drugs
brinzolamidebrimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01310777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310777.